Company Active LTD

Company profile

Domainex Limited

Drug Discovery Services | Enrich Your Medicines Pipeline | Domainex

Enrich your medicines pipeline - Domainex provides a complete range of preclinical drug discovery services tailored to meet all your research needs

CRN
04336899
Founded
2001
Age
24

Overview

Legal name
DOMAINEX LIMITED
Region
East of England
Registered address
DOMAINEX LIMITED CHESTERFORD RESEARCH PARK
LITTLE CHESTERFORD
SAFFRON WALDEN
ENGLAND
CB10 1XL
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Domainex Limited
No active corporate controller recorded.

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
-£1,047,147
Employees
117

Company events

Reference milestones and recent Companies House filing stream events.

6 events
29 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

15 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

16 Sep
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNjAxODMxOWFkaXF6a2N4

Published 16 Sep 2024 14:21

10 Dec
2001

Incorporated

Inception

Company registered at Companies House

Public funding

7 awards
First funded
2010
Funded years
2010, 2011, 2012, 2013, 2014, 2015, 2018
Age at first award
8 years

Projects

2018 Feasibility Studies Lead participant

Development of a novel fragment screening platform for G protein-Coupled Receptors

1 May 2018 to 30 Apr 2019

Awarded
£118,317
Total cost £169,024

"G-protein coupled receptors (GPCRs) are proteins found on the surface of cells: they detect molecules outside the cell and consequently activate internal signalling pathways that mediate cellular responses. GPCRs are one of the most important human drug target classes, and are addressed by 25-30% of marketed drugs. Many GPCRs that are known to have disea...

2015 Feasibility Studies Lead participant

NSD inhibitors for the treatment of multiple myeloma and other cancers

1 Oct 2015 to 31 Dec 2016

Awarded
£139,883
Total cost £199,833

Our aim is to establish the feasibility of finding a new treatment for cancer by targeting a family of three enzymes called the NSDs. Recent academic research has shown that in myeloma and some other types of cancer the NSD family can switch on the production of other proteins that help these cancers grow. This work leads us to believe that a drug which c...

2014 Collaborative R&D Lead participant

Development of a new treatment for Chronic Obstructive Pulmonary Disease

1 Oct 2014 to 30 Sep 2017

Awarded
£1,215,100
Total cost £2,025,167

This project aims to deliver an advanced candidate drug for the treatment for Chronic Obstructive Pulmonary Disease (sometimes refered to as emphysema or chronic bronchitis) – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-...

2013 Feasibility Studies Lead participant

Proving the feasibility of using SMYD3 inhibitors as therapeutics for treatment of hepatocellular carcinoma and other cancers.

1 Feb 2013 to 31 Jan 2014

Awarded
£150,000
Total cost £205,104

Our aim is to establish the feasibility of a new treatment for cancer that works by targeting the enzyme SMYD3. Recent academic research has shown that SMYD3 is not present in normal cells, but in many cancer cells it switches on the production of other proteins that help tumours grow and spread throughout the body. So this work suggests that a drug that ...

2012 Feasibility Studies Lead participant

Proving the feasibility of IKKe inhibitors as therapeutics for treatment of Chronic Obstructive Pulmonary Disease (COPD)

1 Oct 2012 to 31 Jan 2014

Awarded
£150,000
Total cost £200,004

This project aims to establish the feasibility of a new treatment for Chronic Obstructive Pulmonary Disease – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-care burden is huge. Treatment for COPD usually involves relieving...

2011 GRD Development of Prototype Lead participant

A new drug targeting the enzymes TBK1 and IKKe for the treatment of cancer

1 Nov 2011 to 31 Jan 2013

Awarded
£250,000
Total cost £569,790

Our aim is to invent a new drug for the treatment of several common cancers through inhibition of the enzymes IKKe and/or TBK1. Recent academic research has shown that blocking these closely-related protein kinases will stop cancer cells growing, and force them to die. Furthermore these enzymes are important in some inflamatory diseases, obesity, and Type...

2010 Feasibility Studies Lead participant

Novel assays and platforms for testing and controlling regenerative medicine products

1 Aug 2010 to 31 Mar 2011

Awarded
£102,060
Total cost £136,080

Awaiting Public Summary

Product types

Collaborative R&D Feasibility Studies GRD Development of Prototype